Levodopa ameliorated anorectal constipation in de novo Parkinson's disease: The QL-GAT study

Parkinsonism and Related Disorders

Volumn 17, Issue 9, 2011, Pages 662-666

  Tateno, Fuyuki ^a   Sakakibara, Ryuji ^a   Yokoi, Yuko ^b   Kishi, Masahiko ^a   Ogawa, Emina ^a   Uchiyama, Tomoyuki ^c   Yamamoto, Tatsuya ^c   Yamanishi, Tomonori ^d   Takahashi, Osamu ^b  

^a TOHO UNIVERSITY SAKURA MEDICAL CENTER   (Japan)

^b TOHO UNIVERSITY   (Japan)

^c CHIBA UNIVERSITY   (Japan)

^d DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Bowel function; Dopamine; Levodopa; Parkinson's disease; The quantitative lower gastrointestinal autonomic test (QL GAT)

Indexed keywords

CARBIDOPA; LAXATIVE; LEVODOPA;

ABDOMINAL PRESSURE; ADULT; AGED; ANORECTAL CONSTIPATION; ANORECTAL DISEASE; ANORECTAL PRESSURE; ARTICLE; CLINICAL ARTICLE; COLON; CONSTIPATION; CONTROLLED STUDY; DEFECATION DISORDER; DEFECATION HABIT; DISEASE DURATION; DRUG RESPONSE; DRUG TOLERABILITY; FECES INCONTINENCE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTESTINE CONTRACTION; INTESTINE TRANSIT TIME; MALE; MANOMETRY; MOTOR PERFORMANCE; PARKINSON DISEASE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; QUANTITATIVE LOWER GASTROINTESTINAL AUTONOMIC TEST; UNSPECIFIED SIDE EFFECT; VOMITING;

AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; CARBIDOPA; CONSTIPATION; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 80054857517     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2011.06.002     Document Type: Article

References (32)

1. Lees A.J., Hardy J., Revesz T. Parkinson's disease. Lancet 2009, 373(9680):2055-2066.
2. Chaudhuri K.R., Schapira A.H. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009, 8:464-474.
3. Bushmann M., Dobmeyer S.M., Leeker L., Perlmutter J.S. Swallowing abnormalities and their response to treatment in Parkinson's disease. Neurology 1989, 39:1309-1314.
4. Levein N.G., Thorn S.E., Wattwil M. Dopamine delays gastric emptying and prolongs orocaecal transit time in volunteers. Eur J Anaesthesiol 1999, 16:246-250.
5. Uchiyama T., Sakakibara R., Hattori T., Yamanishi T. Short-term effect of a single levodopa dose on micturition disturbance in Parkinson's disease patients with the wearing-off phenomenon. Mov Disord 2003, 18:573-578.
6. Sakakibara R., Odaka T., Liu Z., Uchiyama T., Yamamoto T., Ito T., et al. Dietary herb extract Dai-Kenchu-To ameliorates constipation in parkinsonian patients. Mov Disord 2005, 20:261-262.
7. Liu Z., Sakakibara R., Odaka T., Uchiyama T., Yamamoto T., Ito T., et al. Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients. Mov Disord 2005, 20:680-686.
8. Sakakibara R., Yamaguchi C., Uchiyama T., Yamamoto T., Ito T., Liu Z., et al. Calcium polycarbophil improves constipation in primary autonomic failure and multiple system atrophy subjects. Mov Disord 2007, 22:1672-1673.
9. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992, 55:181-184.
10. Ando Y., Obayashi K., Tanaka Y., Tsuji T., Uchino M., Takahashi M., et al. Radiolabelled meta-iodobenzylguanidine in assessment of autonomic dysfunction. Lancet 1994, 343:984-985.
11. Sakakibara R., Uchiyama T., Yamanishi T., Kishi M. Sphincter EMG as a diagnostic tool in autonomic disorders. Clin Auton Res 2009, 19:20-31.
12. Sakakibara R., Shinotoh H., Uchiyama T., Sakuma M., Kashiwado M., Yoshiyama M., et al. Questionnaire-based assessment of pelvic organ dysfunction in Parkinson's disease. Auton Neurosci Basic Clin 2001, 92:76-85.
13. Sakakibara R., Odaka T., Uchiyama T., Asahina M., Yamaguchi K., Yamaguchi T., et al. Colonic transit time and rectoanal videomanometry in Parkinson's disease. J Neurol Neurosurg Psychiatry 2003, 74:268-272.
14. Sakakibara R., Uchiyama T., Yamanishi T., Shirai K., Hattori T. Bladder and bowel dysfunction in Parkinson's disease. J Neural Transm 2008, 115:443-460.
15. Fontana G.A., Pantaleo T., Lavorini F., Benvenuti F., Gagemi S. Defective motor control of coughing in Parkinson's disease. Am J Respir Crit Care Med 1998, 158:458-464.
16. Mathers S.E., Kempster P.A., Law P.J., Frankel J.P., Bartram C.I., Lees A.J., et al. Anal sphincter dysfunction in Parkinson's disease. Arch Neurol 1989, 46:1061-1064.
17. Amborova P., Hubka1 P., Ulkova I., Hulin I. The pacemaker activity of interstitial cells of Cajal and gastric electrical activity. Physiol Res 2003, 52:275-284.
18. Haskel Y., Hanani M. Inhibition of GI motility by MPTP via adrenergic and dopaminergic mechanisms. Dig Dis Sci 1994, 39:2364-2367.
19. Banach T., Zurowski D., Gil K., Krygowska-Wajs A., Marszalek A., Thor P.J. Peripheral mechanisms of intestinal dysmotility in rats with salsolinol induced experimental Parkinson's disease. J Physiol Pharmacol 2006, 57:291-300.
20. Liu M.T., Rayport S., Jiang L., Murphy D.L., Gershon M.D. Expression and function of 5-HT3 receptors in the enteric neurons of mice lacking the serotonin transporter. Am J Physiol Gastrointest Liver Physiol 2002, 283:G1398-G1411.
21. Li Z.S., Schmauss C., Cuenca A., Ratcliffe E., Gershon M.D. Physiological modulation of intestinal motility by enteric dopaminergic neurons and the D2 receptor: analysis of dopamine receptor expression, location, development, and function in wild-type and knock-out mice. J Neurosci 2006, 26:2798-2807.
22. Vaughan C.J., Aherne A.M., Lane E., Power O., Carey R.M., O'Connell D.P. Identification and regional distribution of the dopamine D1A receptor in the GI tract. Am J Physiol Regul Integr Comp Physiol 2000, 279:R599-R609.
23. Dive A., Foret F., Jamart J., bulpa P., Installe E. Effect of dopamine on GI motility during critical illness. Intensive Care Med 2000, 26:901-907.
24. Lanfranchi G.A., Bazzocchi G., Fois F., Brignola C., Campieri M., Menni B. Effect of domperidone and dopamine on colonic motor activity in patients with the irritable bowel syndrome. Eur J Clin Pharmacol 1985, 29:307-310.
25. Selby W. Complete small-bowel transit in patients undergoing capsule endoscopy: determining factors and improvement with metoclopramide. Gastrointest Endosc 2005, 61:80-85.
26. De Schepper A., Wollaert F., Reyntjens A. Effects of oral domperidone on gastric emptying and motility. A double-blind comparison with placebo and metoclopramide. Arzneimittelforschung 1978, 28:1196-1199.
27. Tollesson P.O., Cassuto J., Faxén A., Rimbäck G., Mattsson E., Rosén S. Lack of effect of metoclopramide on colonic motility after cholecystectomy. Eur J Surg 1991, 157:355-358.
28. Jing H., Lin K.W., Mei M.H. Participation of dopamine on the muscarinergic inhibitory effect of substance P on gastric myoelectric activity and motility. Sheng Li Xue Bao 1995, 47:245-252.
29. Bueno L., Gue M., Fabre C., Junien J.L. Involvement of central dopamine and D1 receptors in stress-induced colonic motor alterations in rats. Brain Res Bull 1992, 29:135-140.
30. Mayer E.A., Aziz Q., Coen S., Kern M., Labus J.S., Lane R., et al. Brain imaging approaches to the study of functional GI disorders: a Rome working team report. Neurogastroenterol Motil 2009, 21:579-596.
31. Oettle G.J. Effect of moderate exercise on bowel habit. Gut 1991, 32:941-944.
32. Meshkinpour H., Selod S., Movahedi H., Nami N., James N., Wilson A. Effects of regular exercise in management of chronic i44diopathic constipation. Dig Dis Sci 1998, 43:2379-2383.